Log In
BCIQ
Print this Print this
 

BMS-986016

  Manage Alerts
Collapse Summary General Information
Company Bristol-Myers Squibb Co.
DescriptionAnti-LAG3 mAb
Molecular Target Lymphocyte-activation gene 3 (LAG3) (CD223)
Mechanism of ActionAntibody
Therapeutic ModalityBiologic: Antibody

 Product Details
Disease CategoryStandard IndicationIndication DetailsPartnersMilestonesLatest Stage of DevelopmentRegulatory Designation
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

0

0

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

07/24/2014

Undisclosed

Undisclosed

Undisclosed

Get a free BioCentury trial today